A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2007-07-24

AUTHORS

H-C Jeung, S Y Rha, S J Shin, J B Ahn, S H Noh, J K Roh, H C Chung

ABSTRACT

Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status. In this paper, we describe the first study to evaluate S-1 monotherapy as an option for advanced gastric cancer patients who are not candidates for combination chemotherapy due to poor clinical condition. Fifty-two patients with Eastern Cooperative Oncology Group (ECOG) performance scale 2–3, whose general condition had made use of combination chemotherapy impossible, were enrolled. S-1 was administered to 30 patients as second- or third-line therapy. The initial dose of S-1 was 35 mg m−2, administered b.i.d for 14 days every 3 weeks. With a median follow-up period of 33 weeks, the median progression-free survival, and overall survival were 11 weeks (95% CI, 8–14) and 33 weeks (95% CI, 19–47), respectively. The overall 1-year survival rate was 29% by intent-to-treat analysis. The overall response rate was 12% (95% CI, 3–21), and the percentage of stable disease was 35%, resulting in the disease control rate of 47% (95% CI, 32–60). Significant drug-related toxicity included grade 3 diarrhoea (14%), anorexia (14%), fatigue (10%), neutropenia (10%), and leucopenia (6%). In conclusion, this study indicated the modest activity of S-1 in gastric cancer patients with poor performance status. More... »

PAGES

458-463

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6603902

DOI

http://dx.doi.org/10.1038/sj.bjc.6603902

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032566320

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17653073


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxonic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tegafur", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jeung", 
        "givenName": "H-C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea", 
            "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rha", 
        "givenName": "S Y", 
        "id": "sg:person.01036404665.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea", 
            "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shin", 
        "givenName": "S J", 
        "id": "sg:person.011321544242.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011321544242.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea", 
            "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ahn", 
        "givenName": "J B", 
        "id": "sg:person.010673374672.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673374672.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea", 
            "Department of Surgery, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noh", 
        "givenName": "S H", 
        "id": "sg:person.01120377020.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120377020.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea", 
            "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roh", 
        "givenName": "J K", 
        "id": "sg:person.0767622633.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea", 
            "Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "H C", 
        "id": "sg:person.016554426212.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6603468", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026961645", 
          "https://doi.org/10.1038/sj.bjc.6603468"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10120-005-0351-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024546340", 
          "https://doi.org/10.1007/s10120-005-0351-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-006-0265-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013466559", 
          "https://doi.org/10.1007/s00280-006-0265-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10120-004-0306-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001554172", 
          "https://doi.org/10.1007/s10120-004-0306-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10120-003-0230-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007479617", 
          "https://doi.org/10.1007/s10120-003-0230-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-07-24", 
    "datePublishedReg": "2007-07-24", 
    "description": "Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status. In this paper, we describe the first study to evaluate S-1 monotherapy as an option for advanced gastric cancer patients who are not candidates for combination chemotherapy due to poor clinical condition. Fifty-two patients with Eastern Cooperative Oncology Group (ECOG) performance scale 2\u20133, whose general condition had made use of combination chemotherapy impossible, were enrolled. S-1 was administered to 30 patients as second- or third-line therapy. The initial dose of S-1 was 35\u2009mg\u2009m\u22122, administered b.i.d for 14 days every 3 weeks. With a median follow-up period of 33 weeks, the median progression-free survival, and overall survival were 11 weeks (95% CI, 8\u201314) and 33 weeks (95% CI, 19\u201347), respectively. The overall 1-year survival rate was 29% by intent-to-treat analysis. The overall response rate was 12% (95% CI, 3\u201321), and the percentage of stable disease was 35%, resulting in the disease control rate of 47% (95% CI, 32\u201360). Significant drug-related toxicity included grade 3 diarrhoea (14%), anorexia (14%), fatigue (10%), neutropenia (10%), and leucopenia (6%). In conclusion, this study indicated the modest activity of S-1 in gastric cancer patients with poor performance status.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6603902", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "97"
      }
    ], 
    "keywords": [
      "poor performance status", 
      "gastric cancer patients", 
      "advanced gastric cancer patients", 
      "performance status", 
      "cancer patients", 
      "combination chemotherapy", 
      "median progression-free survival", 
      "significant drug-related toxicity", 
      "grade 3 diarrhea", 
      "treatment-related toxicity", 
      "third-line therapy", 
      "disease control rate", 
      "phase II study", 
      "poor clinical condition", 
      "progression-free survival", 
      "drug-related toxicity", 
      "overall response rate", 
      "median follow", 
      "stable disease", 
      "systemic chemotherapy", 
      "overall survival", 
      "II study", 
      "treat analysis", 
      "initial dose", 
      "control rate", 
      "gastric cancer", 
      "clinical conditions", 
      "patients", 
      "response rate", 
      "survival rate", 
      "chemotherapy", 
      "modest activity", 
      "weeks", 
      "monotherapy", 
      "survival", 
      "Scale-2", 
      "status", 
      "general condition", 
      "first study", 
      "toxicity", 
      "neutropenia", 
      "leucopenia", 
      "diarrhea", 
      "anorexia", 
      "therapy", 
      "follow", 
      "cancer", 
      "disease", 
      "dose", 
      "study", 
      "rate", 
      "days", 
      "conclusion", 
      "options", 
      "fatigue", 
      "percentage", 
      "period", 
      "activity", 
      "intent", 
      "use", 
      "candidates", 
      "conditions", 
      "analysis", 
      "cycle", 
      "paper"
    ], 
    "name": "A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status", 
    "pagination": "458-463", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032566320"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6603902"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17653073"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6603902", 
      "https://app.dimensions.ai/details/publication/pub.1032566320"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_451.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6603902"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603902'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603902'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603902'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603902'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      22 PREDICATES      117 URIs      104 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6603902 schema:about N026410997e2743df816eecb4dbb6d857
2 N094cf5fb264f4cc6a405ec7796273ab5
3 N1407174bd3dd4700a36b3318b065d3b4
4 N20add7f5fc154b70a4b412b8eccc9579
5 N29908bc76c6c42eab3b7aa6c5724f401
6 N2b219987c12d4f77a624e864cd30dc5e
7 N2b38320374e74a7d8afda47aa12aae14
8 N3055a21fc8fc4746b8f170250fde652b
9 N433706b7a59d4d7296824d6aa5209ef8
10 N45e33b524d26423daf6e0f166b84b88f
11 N5ef7819c349a41d9b1bbc19a5d79a49d
12 N61fc3fb97c854d3b9b171f9f5eeac838
13 N877e04dca17f4d4189f851ce39e339df
14 Naad31fb6cd224600a85a8397087d6768
15 Nbd8871345fce4c9ab28393837534c113
16 Nc101c9654a474b4facefee548b90af64
17 Nc2d8a8b019024b1c95338c288b085da2
18 Nc5d7dab1a10f4119ae866412115615eb
19 Nc6bd4b351b4244a09214265736963c55
20 Nfac519177a044787b12879097699e1be
21 Nfec53a52a0e141fcb3029c8505d84a83
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N7fb70c9f2b7c43d8b737c3f6beccfb23
25 schema:citation sg:pub.10.1007/s00280-006-0265-y
26 sg:pub.10.1007/s10120-003-0230-y
27 sg:pub.10.1007/s10120-004-0306-3
28 sg:pub.10.1007/s10120-005-0351-6
29 sg:pub.10.1038/sj.bjc.6603468
30 schema:datePublished 2007-07-24
31 schema:datePublishedReg 2007-07-24
32 schema:description Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status. In this paper, we describe the first study to evaluate S-1 monotherapy as an option for advanced gastric cancer patients who are not candidates for combination chemotherapy due to poor clinical condition. Fifty-two patients with Eastern Cooperative Oncology Group (ECOG) performance scale 2–3, whose general condition had made use of combination chemotherapy impossible, were enrolled. S-1 was administered to 30 patients as second- or third-line therapy. The initial dose of S-1 was 35 mg m−2, administered b.i.d for 14 days every 3 weeks. With a median follow-up period of 33 weeks, the median progression-free survival, and overall survival were 11 weeks (95% CI, 8–14) and 33 weeks (95% CI, 19–47), respectively. The overall 1-year survival rate was 29% by intent-to-treat analysis. The overall response rate was 12% (95% CI, 3–21), and the percentage of stable disease was 35%, resulting in the disease control rate of 47% (95% CI, 32–60). Significant drug-related toxicity included grade 3 diarrhoea (14%), anorexia (14%), fatigue (10%), neutropenia (10%), and leucopenia (6%). In conclusion, this study indicated the modest activity of S-1 in gastric cancer patients with poor performance status.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree true
36 schema:isPartOf N54761d081523437486d4a72bc007eb08
37 Nfafc7b6420284d99adfe225cda44081a
38 sg:journal.1017082
39 schema:keywords II study
40 Scale-2
41 activity
42 advanced gastric cancer patients
43 analysis
44 anorexia
45 cancer
46 cancer patients
47 candidates
48 chemotherapy
49 clinical conditions
50 combination chemotherapy
51 conclusion
52 conditions
53 control rate
54 cycle
55 days
56 diarrhea
57 disease
58 disease control rate
59 dose
60 drug-related toxicity
61 fatigue
62 first study
63 follow
64 gastric cancer
65 gastric cancer patients
66 general condition
67 grade 3 diarrhea
68 initial dose
69 intent
70 leucopenia
71 median follow
72 median progression-free survival
73 modest activity
74 monotherapy
75 neutropenia
76 options
77 overall response rate
78 overall survival
79 paper
80 patients
81 percentage
82 performance status
83 period
84 phase II study
85 poor clinical condition
86 poor performance status
87 progression-free survival
88 rate
89 response rate
90 significant drug-related toxicity
91 stable disease
92 status
93 study
94 survival
95 survival rate
96 systemic chemotherapy
97 therapy
98 third-line therapy
99 toxicity
100 treat analysis
101 treatment-related toxicity
102 use
103 weeks
104 schema:name A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
105 schema:pagination 458-463
106 schema:productId N18352cdcc4884222a685d316d629f7aa
107 Nce170d876e024a3ea647f9f684cff9e9
108 Nf844e422ba5c45f2af7818ab9975b597
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032566320
110 https://doi.org/10.1038/sj.bjc.6603902
111 schema:sdDatePublished 2022-05-20T07:24
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N8eeea2ed043f4976b1f9d3d0fbcf8bc5
114 schema:url https://doi.org/10.1038/sj.bjc.6603902
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N026410997e2743df816eecb4dbb6d857 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Aged
120 rdf:type schema:DefinedTerm
121 N094cf5fb264f4cc6a405ec7796273ab5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Treatment Outcome
123 rdf:type schema:DefinedTerm
124 N1407174bd3dd4700a36b3318b065d3b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Adult
126 rdf:type schema:DefinedTerm
127 N18352cdcc4884222a685d316d629f7aa schema:name pubmed_id
128 schema:value 17653073
129 rdf:type schema:PropertyValue
130 N20add7f5fc154b70a4b412b8eccc9579 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Drug Administration Schedule
132 rdf:type schema:DefinedTerm
133 N29908bc76c6c42eab3b7aa6c5724f401 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Middle Aged
135 rdf:type schema:DefinedTerm
136 N2b05a5c4c45c4bab98be5d992c179c7b rdf:first sg:person.01120377020.04
137 rdf:rest Nba39153e48794ca98ab1302c0871a1d6
138 N2b219987c12d4f77a624e864cd30dc5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Survival Analysis
140 rdf:type schema:DefinedTerm
141 N2b38320374e74a7d8afda47aa12aae14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Adenocarcinoma
143 rdf:type schema:DefinedTerm
144 N3055a21fc8fc4746b8f170250fde652b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Tegafur
146 rdf:type schema:DefinedTerm
147 N38fd3d29c16140328dbdb2d9b63a1011 rdf:first sg:person.016554426212.74
148 rdf:rest rdf:nil
149 N433706b7a59d4d7296824d6aa5209ef8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Antimetabolites, Antineoplastic
151 rdf:type schema:DefinedTerm
152 N439635bd286547a3a6e4fce6337181d7 rdf:first sg:person.01036404665.54
153 rdf:rest Na741c7f948544eb2a2e0961a496431d1
154 N45e33b524d26423daf6e0f166b84b88f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Aged, 80 and over
156 rdf:type schema:DefinedTerm
157 N54761d081523437486d4a72bc007eb08 schema:issueNumber 4
158 rdf:type schema:PublicationIssue
159 N5981a2758170420ca447e9ae6f7e4de0 schema:affiliation grid-institutes:grid.15444.30
160 schema:familyName Jeung
161 schema:givenName H-C
162 rdf:type schema:Person
163 N5ef7819c349a41d9b1bbc19a5d79a49d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Disease Progression
165 rdf:type schema:DefinedTerm
166 N61fc3fb97c854d3b9b171f9f5eeac838 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Feasibility Studies
168 rdf:type schema:DefinedTerm
169 N6f12cdd4adc3465aadf25d726994753b rdf:first sg:person.010673374672.49
170 rdf:rest N2b05a5c4c45c4bab98be5d992c179c7b
171 N7fb70c9f2b7c43d8b737c3f6beccfb23 rdf:first N5981a2758170420ca447e9ae6f7e4de0
172 rdf:rest N439635bd286547a3a6e4fce6337181d7
173 N877e04dca17f4d4189f851ce39e339df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Prognosis
175 rdf:type schema:DefinedTerm
176 N8eeea2ed043f4976b1f9d3d0fbcf8bc5 schema:name Springer Nature - SN SciGraph project
177 rdf:type schema:Organization
178 Na741c7f948544eb2a2e0961a496431d1 rdf:first sg:person.011321544242.27
179 rdf:rest N6f12cdd4adc3465aadf25d726994753b
180 Naad31fb6cd224600a85a8397087d6768 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Drug Combinations
182 rdf:type schema:DefinedTerm
183 Nba39153e48794ca98ab1302c0871a1d6 rdf:first sg:person.0767622633.82
184 rdf:rest N38fd3d29c16140328dbdb2d9b63a1011
185 Nbd8871345fce4c9ab28393837534c113 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Stomach Neoplasms
187 rdf:type schema:DefinedTerm
188 Nc101c9654a474b4facefee548b90af64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Humans
190 rdf:type schema:DefinedTerm
191 Nc2d8a8b019024b1c95338c288b085da2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Male
193 rdf:type schema:DefinedTerm
194 Nc5d7dab1a10f4119ae866412115615eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Oxonic Acid
196 rdf:type schema:DefinedTerm
197 Nc6bd4b351b4244a09214265736963c55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Female
199 rdf:type schema:DefinedTerm
200 Nce170d876e024a3ea647f9f684cff9e9 schema:name doi
201 schema:value 10.1038/sj.bjc.6603902
202 rdf:type schema:PropertyValue
203 Nf844e422ba5c45f2af7818ab9975b597 schema:name dimensions_id
204 schema:value pub.1032566320
205 rdf:type schema:PropertyValue
206 Nfac519177a044787b12879097699e1be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Follow-Up Studies
208 rdf:type schema:DefinedTerm
209 Nfafc7b6420284d99adfe225cda44081a schema:volumeNumber 97
210 rdf:type schema:PublicationVolume
211 Nfec53a52a0e141fcb3029c8505d84a83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Time Factors
213 rdf:type schema:DefinedTerm
214 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
215 schema:name Medical and Health Sciences
216 rdf:type schema:DefinedTerm
217 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
218 schema:name Oncology and Carcinogenesis
219 rdf:type schema:DefinedTerm
220 sg:journal.1017082 schema:issn 0007-0920
221 1532-1827
222 schema:name British Journal of Cancer
223 schema:publisher Springer Nature
224 rdf:type schema:Periodical
225 sg:person.01036404665.54 schema:affiliation grid-institutes:grid.15444.30
226 schema:familyName Rha
227 schema:givenName S Y
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54
229 rdf:type schema:Person
230 sg:person.010673374672.49 schema:affiliation grid-institutes:grid.15444.30
231 schema:familyName Ahn
232 schema:givenName J B
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673374672.49
234 rdf:type schema:Person
235 sg:person.01120377020.04 schema:affiliation grid-institutes:grid.15444.30
236 schema:familyName Noh
237 schema:givenName S H
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120377020.04
239 rdf:type schema:Person
240 sg:person.011321544242.27 schema:affiliation grid-institutes:grid.15444.30
241 schema:familyName Shin
242 schema:givenName S J
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011321544242.27
244 rdf:type schema:Person
245 sg:person.016554426212.74 schema:affiliation grid-institutes:grid.15444.30
246 schema:familyName Chung
247 schema:givenName H C
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74
249 rdf:type schema:Person
250 sg:person.0767622633.82 schema:affiliation grid-institutes:grid.15444.30
251 schema:familyName Roh
252 schema:givenName J K
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82
254 rdf:type schema:Person
255 sg:pub.10.1007/s00280-006-0265-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1013466559
256 https://doi.org/10.1007/s00280-006-0265-y
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/s10120-003-0230-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1007479617
259 https://doi.org/10.1007/s10120-003-0230-y
260 rdf:type schema:CreativeWork
261 sg:pub.10.1007/s10120-004-0306-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001554172
262 https://doi.org/10.1007/s10120-004-0306-3
263 rdf:type schema:CreativeWork
264 sg:pub.10.1007/s10120-005-0351-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024546340
265 https://doi.org/10.1007/s10120-005-0351-6
266 rdf:type schema:CreativeWork
267 sg:pub.10.1038/sj.bjc.6603468 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026961645
268 https://doi.org/10.1038/sj.bjc.6603468
269 rdf:type schema:CreativeWork
270 grid-institutes:grid.15444.30 schema:alternateName Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
271 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
272 Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
273 schema:name Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
274 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
275 Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...